Navigation Links
Dendreon Announces Webcast Presentation at Credit Suisse 2010 Health Care Conference
Date:11/5/2010

SEATTLE, Nov. 5, 2010 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that management will present at the Credit Suisse 2010 Health Care Conference, Phoenix, AZ on November 11, 2010 at 1:30 p.m. ET.

The presentation will be audio webcast live and available for replay from Dendreon's website, www.dendreon.com.  If you are unable to listen to the live webcast, it will be archived on the site following the presentation. To access the replay, go to the Investor Relations section of the website.

Dendreon Corporation is a biotechnology company whose mission is to target cancer and transform lives through the discovery, development, commercialization and manufacturing of novel therapeutics. The Company applies its expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates designed to stimulate an immune response in a variety of tumor types. Dendreon's first product, PROVENGE®, was approved by the FDA in April 2010. Dendreon is exploring the application of additional ACI product candidates and small molecules for the potential treatment of a variety of cancers. The Company is headquartered in Seattle, Washington and is traded on the NASDAQ Global Market under the symbol DNDN. For more information about the Company and its programs, visit http://www.dendreon.com/.


'/>"/>
SOURCE Dendreon Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. Dendreon Completes Target Enrollment of 500 Patients in Phase 3 IMPACT Study of Provenge(R) For Advanced Prostate Cancer
3. Dendreon Presents Data Correlating the Cumulative Potency of PROVENGE(R) to Overall Survival
4. Dendreon Presents Preclinical Data Demonstrating Activity of Trp-p8 agonist, D-3263, in Benign Prostatic Hyperplasia
5. Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
6. Dendreon Expects Interim Data Analysis for Phase 3 PROVENGE IMPACT Trial in October
7. Dendreon to Hold a Conference Call Today at 9:00 AM ET to Provide an Update on Interim Results of Phase 3 PROVENGE IMPACT Trial
8. Dendreon Announces Interim Data From Phase 3 PROVENGE IMPACT Trial
9. Dendreon Presents Integrated Analysis of Clinical Data from NEUVENGE Trials at Chemotherapy Foundation Symposium
10. Dendreon to Hold a Conference Call Tomorrow at 9:00 AM ET to Discuss Final Results of Phase 3 PROVENGE IMPACT Trial
11. Dendreon Initiates Phase 1 Clinical Trial of Small Molecule Targeting TRPM8 in Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2016)... -- According to market research "Global Insulin ... Forecast to 2022 - Industry Insights by Type (Insulin ... P&S Market Research, the global insulin delivery device market ... is expected to grow at a CAGR of 6.6% ... is expected to witness the fastest growth at a ...
(Date:5/25/2016)... England , May 25, 2016 ... company employing the precision of circulating tumour DNA ... today announces the appointment of Professor Clive ... provide medical leadership across the clinical development programme, ... Inivata,s products help deliver significant improvements in clinical ...
(Date:5/24/2016)... , May 24, 2016   ... endpoints demonstrating non-inferiority in overall bowel cleansing and superiority ... c leansing of the ... http://photos.prnewswire.com/prnh/20130829/633895-a ) , Norgine B.V. today announced new ... litre PEG and ascorbate bowel preparation) versus standard 2 litre PEG ...
Breaking Medicine Technology:
(Date:5/26/2016)... ... May 26, 2016 , ... Bunion Bootie , the manufacturer ... treatment was more than humbled by customer demand over the Mother’s Day Weekend promotion. ... sale. Now that Bunion Bootie has completely replenished its inventory levels, it hopes to ...
(Date:5/26/2016)... ... ... The introduction of our professional athletes coincides with the company’s new campaign: “LOOK ... are proud to introduce Meghan Klingenberg, defender and World Champion with the US Women’s ... Los Angeles who was a second round selection in the 2012 NFL draft. We ...
(Date:5/26/2016)... ... 2016 , ... May 2016 – Lips may be a central feature on ... Record numbers of clients now ask about lip plumping and primping techniques and want ... of Advanced Dermatology P.C. , The trend is a national one, with ...
(Date:5/26/2016)... Viejo, California (PRWEB) , ... May 26, 2016 , ... ... Transition Plugin for FCPX. , "This new layered style transition tool will ... said Christina Austion - CEO of Pixel Film Studios. , TranSweep is an ...
(Date:5/26/2016)... OR (PRWEB) , ... May 26, 2016 , ... According ... customs. In an industry filled with chemical-laden beauty products, one company is going against ... good for you: Mad Hippie. The rising star in the green space is proud ...
Breaking Medicine News(10 mins):